Literature DB >> 20193680

Calpains: markers of tumor aggressiveness?

Hélène Roumes1, Ludovic Leloup, Elise Dargelos, Jean-Jacques Brustis, Laetitia Daury, Patrick Cottin.   

Abstract

Rhabdomyosarcoma (RMS) are soft-tissue sarcoma commonly encountered in childhood. RMS cells can acquire invasive behavior and form metastases. The metastatic dissemination implicates many proteases among which are mu-calpain and m-calpain. Study of calpain expression and activity underline the deregulation of calpain activity in RMS. Analysis of kinetic characteristics of RMS cells, compared to human myoblasts LHCN-M2 cells, shows an important migration velocity in RMS cells. One of the major results of this study is the positive linear correlation between calpain activity and migration velocity presenting calpains as a marker of tumor aggressiveness. The RMS cytoskeleton is disorganized. Specifying the role of mu- and m-calpain using antisense oligonucleotides led to show that both calpains up-regulate alpha- and beta-actin in ARMS cells. Moreover, the invasive behavior of these cells is higher than that of LHCN-M2 cells. However, it is similar to that of non-treated LHCN-M2 cells, when calpains are inhibited. In summary, calpains may be involved in the anarchic adhesion, migration and invasion of RMS. The direct relationship between calpain activity and migration velocities or invasive behavior indicates that calpains could be considered as markers of tumor aggressiveness and as potential targets for limiting development of RMS tumor as well as their metastatic behavior. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193680     DOI: 10.1016/j.yexcr.2010.02.017

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Recombinant protein rVP1 upregulates BECN1-independent autophagy, MAPK1/3 phosphorylation and MMP9 activity via WIPI1/WIPI2 to promote macrophage migration.

Authors:  Chiao-Chun Liao; Ming-Yi Ho; Shu-Mei Liang; Chi-Ming Liang
Journal:  Autophagy       Date:  2012-10-10       Impact factor: 16.016

Review 2.  The calpain system and cancer.

Authors:  Sarah J Storr; Neil O Carragher; Margaret C Frame; Tim Parr; Stewart G Martin
Journal:  Nat Rev Cancer       Date:  2011-05       Impact factor: 60.716

Review 3.  Calpains as potential anti-cancer targets.

Authors:  Ludovic Leloup; Alan Wells
Journal:  Expert Opin Ther Targets       Date:  2011-01-19       Impact factor: 6.902

4.  Overexpression of the skNAC gene in human rhabdomyosarcoma cells enhances their differentiation potential and inhibits tumor cell growth and spreading.

Authors:  Janine Berkholz; Weronika Kuzyniak; Michael Hoepfner; Barbara Munz
Journal:  Clin Exp Metastasis       Date:  2014-09-11       Impact factor: 5.150

5.  Human U87 astrocytoma cell invasion induced by interaction of βig-h3 with integrin α5β1 involves calpain-2.

Authors:  Jie Ma; Wei Cui; Shi-ming He; Yong-hong Duan; Li-Jun Heng; Liang Wang; Guo-dong Gao
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

6.  Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor-β-induced expression in urothelial carcinoma.

Authors:  Donghao Shang; Bo Song; Yuting Liu
Journal:  Cancer Sci       Date:  2018-02-20       Impact factor: 6.716

7.  Proteomic Study to Survey the CIGB-552 Antitumor Effect.

Authors:  Arielis Rodríguez-Ulloa; Jeovanis Gil; Yassel Ramos; Lilian Hernández-Álvarez; Lisandra Flores; Brizaida Oliva; Dayana García; Aniel Sánchez-Puente; Alexis Musacchio-Lasa; Jorge Fernández-de-Cossio; Gabriel Padrón; Luis J González López; Vladimir Besada; Maribel Guerra-Vallespí
Journal:  Biomed Res Int       Date:  2015-10-20       Impact factor: 3.411

8.  ACYP2 contributes to malignant progression of glioma through promoting Ca2+ efflux and subsequently activating c-Myc and STAT3 signals.

Authors:  Mengdan Li; Banjun Ruan; Jing Wei; Qi Yang; Mingwei Chen; Meiju Ji; Peng Hou
Journal:  J Exp Clin Cancer Res       Date:  2020-06-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.